
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Blog
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Biotech Radar July 29, 2026: PolyPid Gets Priority Review, Processa Resets Around VT-7208, TScan Starts Phase 3 — $PYPD $PCSA $TCRX

PolyPid receives FDA Priority Review for D-PLEX100, Processa rebuilds around VT-7208 with a $200 million financing, and TScan begins pivotal Phase 3 execution.
Biotech Radar July 28, 2026: Kiniksa Rerates, Nautilus Pushes Voyager Shipments to Mid-2027 and Alkermes Expands Its Sleep Franchise — $KNSA $NAUT $ALKS

Today’s Radar separates a genuine commercial-plus-clinical rerating at Kiniksa from a material commercialization-timeline reset at Nautilus Biotechnology and a strong but more complex post-acquisition quarter at Alkermes. NeoGenomics and Mirion remain on the closing-bell watchlist, with results scheduled after the market closes.
$MSOS $TLRY $CGC $ACB: After the DEA Hearing, the Cannabis Trade Moves Into the Shadows

The courtroom has gone quiet, but the federal cannabis story is becoming more complicated—not less. Behind the August 17 deadline, investors are watching an unfinished tax rule, a dangerous court challenge and a Schedule II scenario that few traders appear prepared to discuss.
Biotech Radar July 27, 2026: Entera Bio ($ENTX), Freenome ($FRNM), Sarepta Therapeutics ($SRPT) and Legend Biotech ($LEGN)

Four biotech stories moved onto the radar for four very different reasons: a company-changing financing at $ENTX, a first commercial FDA approval at $FRNM, a planned leadership handoff at $SRPT and a sudden CEO departure at $LEGN.
Golden Dome Enters the Procurement Era: 108 Tracking Satellites, the FY2027 Funding Fight and What It Means for $LHX $RKLB $LMT $NOC

Golden Dome is no longer only a presidential vision or a broad market narrative. Congress has begun writing oversight into law, billions are moving through missile-warning and tracking awards, and the next political battle is already forming around FY2027 funding, space-based interceptors, acquisition authority and the true cost of defending the U.S. homeland.
Cannabis News Today: DEA Rescheduling, U.S. Hemp and $ACB $TLRY $CRON $CGC

A complete cannabis-sector update: the federal hearing is over, but a decision is not imminent; Congress is split between legalization and an attempt to block rescheduling; industry political donations are rising; and a parallel court fight could delay the process. Meanwhile, Aurora Cannabis, Tilray Brands, Cronos Group and Canopy Growth are looking for company-specific catalysts that do not depend entirely on Washington.
Biotech Radar July 22, 2026: BridgeBio, Curis, Monopar and Others — $BBIO $CRIS $MNPR

Six verified biotech developments published today: an accepted rare-disease NDA, updated PCNSL response data, the opening of a rolling Wilson-disease application, a positive brain-metastases imaging study, a Canadian ALS regulatory path and a $1.5 billion cell-therapy tools acquisition.
Why The Critical-Minerals Race Is Won In The Midstream, Not The Mine ($UAMY, $MP, $USAR, $TMC)

A framework for reading the critical-minerals sector: why the real bottleneck is processing (the midstream), a four-question tool to triage any headline, with $UAMY as the worked example and $MP, $USAR and $TMC on the map.
Priority Review Vouchers Explained: How an FDA Approval Becomes $180-205 Million in Cash, With $RCKT and $DNLI as Worked Examples · $XBI $IBB

How Rare Pediatric Disease Priority Review Vouchers turn a single FDA approval into $180-205 million in non-dilutive cash - the mechanism explained, with $RCKT and $DNLI as worked examples.
Betting on the FDA: How Kalshi’s Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector

Kalshi launched a pilot program on July 16, 2026, enabling trading on clinical trial outcomes and FDA decisions linked to biotech firms. This new prediction market offers a public price reflecting the probability of drug approval, but raises ethical concerns and potential manipulation risks due to limited participant knowledge and liquidity challenges.
The Cannabis Risk That Quietly Died in January: What It Means for $MSOS, $TLRY, $CGC and $ACB

Congress stripped the provision that would have defunded marijuana rescheduling — the House passed the clean bill 397-28 — and cannabis investors never priced it. Meanwhile the sector fell during the DEA hearing itself.
Biotech Radar July 17, 2026: Kalaris, REGENXBIO and Novartis — $KLRS $RGNX $NVS

A full three-company edition covering an early wet-AMD durability signal, a $100 million gene-therapy financing that materially resets per-share ownership, and a traditional FDA approval that raises the evidence standard across the increasingly competitive IgA-nephropathy market.
Why U.S. Defense Stocks Are Correcting: $LMT, $AVAV, $KTOS, $RCAT and the Full Merlintrader Stock-Hub Map

A U.S.-only defense report covering traditional primes, scaled defense-tech, high-beta drone and AI names, and national-security space companies already followed by Merlintrader. The central question is not whether military demand exists, but which companies can turn budgets and contract ceilings into funded backlog, margins and free cash flow per share.
Why Space Stocks Keep Falling: $RKLB, $ASTS, $PL, $LUNR and the July 2026 Reversal Map

The space economy has not stopped growing, but its public-market proxies have lost scarcity, absorbed a wave of new securities and broken key technical support. This report separates the common sector shock from each company’s own risks and identifies what would have to change before the decline can credibly reverse.
Biotech Radar July 16, 2026: Gain Therapeutics, aTyr Pharma and Medicus Pharma — $GANX $ATYR $MDCX

Three biotech updates, three very different evidence problems: an early Parkinson’s disease signal moving toward Phase 2, a post hoc attempt to rescue a pulmonary sarcoidosis program after a missed Phase 3 endpoint, and an FDA-guided protocol optimization that may make a urology study faster and less expensive without yet proving efficacy.
Beyond Nvidia: The Physical AI Infrastructure Chain Behind Defense, Power and Critical Minerals — $BBAI $BE $MP

The AI boom is no longer only a semiconductor and cloud-computing story. It is becoming a race for mission-ready software, deployable electricity and secure magnet supply. This report separates the common narrative from the very different financial realities of BigBear.ai, Bloom Energy and MP Materials.
Cannabis Rescheduling Hearing Final Wrap: What the Record Says for $ACB , $MSOS , $TLRY and $CGC

The July 15 testimony is over. There is no verdict, no vote and no broad Schedule III final rule yet. The hearing nevertheless clarified which parts of the government’s case survived, where the opposition created real legal risk and what investors should watch next.
Biotech Radar — July 15, 2026: Biogen and Ionis — Diranersen Lowers Tau, but CELIA Leaves Clinical Risk Unresolved ($BIIB, $IONS)

Phase 2 CELIA produced one of the most intriguing tau signals yet seen in Alzheimer’s disease, but it did not settle the key issue: why did the lowest dose show the most persuasive cognitive benefit while higher doses failed to produce a stronger response?
$BIIB · $IONS
Alzheimer’s · Tau · Antisense
Biotech Radar July 14, 2026: Biogen ($BIIB), AstraZeneca ($AZN), GSK ($GSK) and Evotec ($EVO)

Merlintrader Biotech Radar Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO A deeper four-company edition covering an FDA delivery breakthrough in Alzheimer’s disease, a $1.5 billion lung-cancer licensing deal, a potentially treatment-changing organ-preservation…
GRVY Stock Hub: Gravity News, Ragnarok Launches and Cash Returns

Online and mobile game publishing.



